RxDoctor Payments Data

Marlene Mires, MD

Family Medicine · Brea, CANPI 1235185976

Payments from drug & device makers

$2,255in general payments, 2019–2025

Across 108 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$398
  • AstraZeneca$233
  • GSK$213
  • Lilly USA, LLC$179
  • Novo Nordisk$145
  • Nova Eye, Inc.$125
  • plus $963 from 23 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$2,19397%
  • Education$422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,255 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$53,166
Medicare patients
146
Services billed
598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$142,086
JanuviaSitagliptin Phosphate64$70,774
EliquisApixaban53$48,288
JardianceEmpagliflozin28$36,737
JanumetSitagliptin Phos/Metformin Hcl23$33,471
TradjentaLinagliptin33$28,068
RybelsusSemaglutide11$22,739
MounjaroTirzepatide16$18,243
SymbicortBudesonide/Formoterol Fumarate17$8,744
PremarinEstrogens, Conjugated24$8,543
Atorvastatin Calcium649$6,980
Spiriva RespimatTiotropium Bromide12$6,950
Levothyroxine Sodium430$6,692
SynthroidLevothyroxine Sodium70$5,671
Ezetimibe135$3,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$145$164,826109 claims
MerckJanuvia, Janumet$99$104,24587 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$110$71,75673 claims
PfizerEliquis, Premarin$398$56,83177 claims
Lilly USA, LLCMounjaro$179$18,24316 claims
AstraZenecaSymbicort$233$8,74417 claims
AbbVieSynthroid$17$5,67170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Brea

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →